期刊文献+

啤酒花活性成分黄腐酚抗骨质疏松作用研究 被引量:4

Anti-osteoporotic study on xanthohumol,an active ingredient in Humulus lupulus L.
下载PDF
导出
摘要 目的对黄腐酚在动物及成骨细胞水平上的抗骨质疏松作用进行评价。方法采用去卵巢小鼠骨质疏松模型进行体内药效学验证。运用Elisa试剂盒及Micro-CT检测方法,对小鼠血清生化指标及股骨骨密度、骨组织形态学进行评价。同时结合成骨细胞增殖、分化和矿化水平分析,以及骨形成相关蛋白的Western blot检测,对黄腐酚抗骨质疏松作用进行系统评价。结果在体内药效学研究中,黄腐酚可显著提高去卵巢小鼠雌激素水平,降低高骨转换率;改善骨小梁微环境,增强骨密度。在成骨细胞水平上,黄腐酚既可以促进成骨细胞增殖、碱性磷酸酶(ALP)活性以及骨矿化水平,又可以提高骨桥蛋白(OPN)、骨涎蛋白(BSP)和骨形成蛋白(BMP-2)的表达。结论本研究首次明确了黄腐酚具有抗骨质疏松作用,为开发治疗骨质疏松的药物提供新的资源。 Objective To evaluate the anti-osteoporotic effect of xanthohumol(XN)in animal and osteoblast.MethodsThe anti-osteoporotic study on XN was performed with ovariectomized mice model.Serum biochemical indexes,bone mineral density(BMD)and bone histomorphology were measured using Elisa kits and Micro-CT analysis.In vitro test,the effect of XN on osteoblastic proliferation,differentiation and mineralization were assayed.The expression of protein related to bone formation was measured by Western blot analysis.Results In vivo experiments,XN significantly increased the estrogen level,reduced the high bone turnover rate,improved the microenvironment and BMD in ovariectomized mice.In vitro experiments,XN protected bone loss not only by promoting osteoblastic proliferation,ALP activity and bone mineralization,but also through increasing the expression of osteopontin(OPN),bone sialoprotein(BSP)and bone morphogenetic protein-2(BMP-2).Conclusion This is the first report to confirm that XN has anti-osteoporotic effect,which provides a new approach for the clinical treatment of osteoporosis.
作者 林柳悦 夏天爽 蒋益萍 李常惠 秦路平 辛海量 LIN Liuyue;XIA Tianshuang;JIANG Yiping;LI Changhui;QIN Luping;XIN Hailiang(School of Pharmacy , Fujian University of Traditional Chinese Medicine , Fuzhou 350122 , China;Department of Pharmacognosy , School of Pharmacy , Second Military Medical University , Shanghai 200433 , China)
出处 《药学实践杂志》 CAS 2018年第3期219-223,共5页 Journal of Pharmaceutical Practice
基金 国家自然科学基金(U1603283)
关键词 黄腐酚 抗骨质疏松 去卵巢 成骨细胞 xanthohumol anti-osteoporosis ovariectomy osteoblast
  • 相关文献

参考文献5

二级参考文献32

  • 1丁桂芝.类胰岛素生长因子对骨代谢的调节作用[J].中国骨质疏松杂志,1995,1(1):73-75. 被引量:12
  • 2邓展生,张璇,邹冬青,向铁成,胡懿合.骨碎补有效成分柚皮甙对人骨髓间充质干细胞的影响[J].湘南学院学报(自然科学版),2005,7(4):5-7. 被引量:23
  • 3Ruza I, Mirfakhraee S, Orwoll E,et al. Clinical experience with in- travenous zoledronic acid in the treatment of male osteoporosis : evi- dence and opinions. Ther Adv Musculoskelet Dis, 2013, 5 (4) : 182 - 198.
  • 4Black DM, Delmas PD, Eastell R, et al. Horizon pivotal fracture trail. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. N Engl J Med, 2007, 356(18) : 1809 - 1822.
  • 5Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid [J]. J Clin Endocrinol Metab, 2010, 95(9): 4380 -4387.
  • 6Green JR, M~iller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, eterocyclic bisphosphonate compound [ J ]. J Bone Miner Res, 1994, 9(5) : 745 -751.
  • 7Dunford JE, Thompson K, Coxon FP,et al. Structure-activity rela- tionships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphos- phonates [J].J Pharmacol Exp Ther, 2001,296 (2) : 235 - 242.
  • 8Dicuonzo G, Vincenzi B, Santini D, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6 [ J ]. J Interferon Cytokine Res, 2003, 23 ( 11 ) : 649 - 654.
  • 9Strampel W, Emkey R, Civitelli R. Safety considerations with bi- sphosphonates for the treatment of osteoporosis [J]. Drug Saf, 2007, 30(9): 755-763.
  • 10Nancollas GH, Tang R, Phipps R J, et al. Novel insights into ac- tions of bisphosphonates on bone: differences in interactions with hydroxyapatite[J]. Bone, 2006, 38(5): 617-627.

共引文献1453

同被引文献43

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部